Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TST001 in Locally Advanced or Metastatic Solid Tumors
NCT04495296Phase 2Active, not recruiting
- Sponsor
- Transcenta
- Start
- Aug 2020
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of osemitamab in solid tumor, gastric cancer (GC), gastroesophageal junction cancer, pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), sponsored by Transcenta. Started Aug 2020; status: active, not recruiting.
02
Drugs
osemitamab
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction cancerpancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04495296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495296.